Literature DB >> 15150689

Response to Chiasson et al.: Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.

P T Sawicki1, T Kaiser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15150689     DOI： 10.1007/s00125-004-1410-y

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  8 in total

1.  Acarbose for patients with hypertension and impaired glucose tolerance.

Authors:  Thomas Kaiser; Peter T Sawicki
Journal:  JAMA       Date:  2003-12-17       Impact factor: 56.272

2.  Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.

Authors:  M Hanefeld; M Cagatay; T Petrowitsch; D Neuser; D Petzinna; M Rupp
Journal:  Eur Heart J       Date:  2004-01       Impact factor: 29.983

3.  Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines.

Authors:  R Cifkova; S Erdine; R Fagard; C Farsang; A M Heagerty; W Kiowski; S Kjeldsen; T Lüscher; J M Mallion; G Mancia; N Poulter; K H Rahn; J L Rodicio; L M Ruilope; P van Zwieten; B Waeber; B Williams; A Zanchetti
Journal:  J Hypertens       Date:  2003-10       Impact factor: 4.844

4.  A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

Authors:  R R Holman; C A Cull; R C Turner
Journal:  Diabetes Care       Date:  1999-06       Impact factor: 19.112

5.  Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data.

Authors:  T Kaiser; P T Sawicki
Journal:  Diabetologia       Date:  2004-01-16       Impact factor: 10.122

6.  The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.

Authors:  J L Chiasson; R Gomis; M Hanefeld; R G Josse; A Karasik; M Laakso
Journal:  Diabetes Care       Date:  1998-10       Impact factor: 19.112

7.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

8.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321
  8 in total
  1 in total

1.  Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.

Authors:  Suzanne Vl Moelands; Peter Lbj Lucassen; Reinier P Akkermans; Wim Jc De Grauw; Floris A Van de Laar
Journal:  Cochrane Database Syst Rev       Date:  2018-12-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.